Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency

This study has been completed.
Information provided by (Responsible Party):
Synageva BioPharma Corp. Identifier:
First received: March 1, 2011
Last updated: June 2, 2014
Last verified: June 2014